DekaBank Deutsche Girozentrale raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,136,934 shares of the biopharmaceutical company’s stock after buying an additional 277,857 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Gilead Sciences were worth $76,555,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Creative Financial Designs Inc. ADV grew its stake in Gilead Sciences by 55.9% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 165 shares during the period. Trustcore Financial Services LLC purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $34,000. Weaver Consulting Group purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $34,000. Legacy Advisors LLC purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $37,000. Finally, Founders Capital Management grew its stake in Gilead Sciences by 50.0% in the 1st quarter. Founders Capital Management now owns 600 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 200 shares during the period. 78.87% of the stock is owned by institutional investors.
Shares of NASDAQ:GILD opened at $64.30 on Wednesday. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The firm’s 50-day simple moving average is $66.43. The company has a market cap of $82.62 billion, a P/E ratio of 10.46, a PEG ratio of 3.10 and a beta of 1.16.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is presently 40.98%.
In related news, EVP Brett A. Pletcher sold 7,200 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the sale, the executive vice president now owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the business’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.
Several research firms have commented on GILD. Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 17th. Credit Suisse Group lowered their target price on shares of Gilead Sciences from $70.00 to $67.00 and set a “neutral” rating for the company in a research note on Wednesday, July 31st. Goldman Sachs Group cut shares of Gilead Sciences from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $70.00 to $60.00 in a research note on Tuesday, May 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Monday, July 15th. Finally, Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a report on Friday, April 26th. They issued an “outperform” rating and a $82.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $82.29.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: Coverage Ratio
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.